Skip to content

A clinical study to evaluate the effect of sarvanga tvagadi alepa in the management of amavata w.s.r to rheumatoid arthritis

A randomised controlled clinical study to evaluate the effect of sarvanga tvagadi alepa in the management of amavata w.s.r to rheumatoid arthritis - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096459
Enrollment
30
Registered
2025-10-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

None listed

Sponsors

Sushmitha K
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients fulfilling diagnostic criteria. Patients who are fit for Alepa chikitsa.

Exclusion criteria

Exclusion criteria: All connective tissue disorders other than Rheumatoid arthritis. Patients with any other systemic illness which will hamper treatment. All patients who are allergic to alepa.

Design outcomes

Primary

MeasureTime frame
Parametric data analysed before and after the study using paired t test for within the group and unpaired t test for between the group. Non parametric data analysed before and after the study using Wilcoxon signed rank test for within the group and Mann Whitney test for between the group. The signs and symptoms will be assessed before treatment on 0th day and after the treatment on 7th day and after 14 days of follow up based on subjective and objective parameters.Timepoint: 14 days

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactPadmakiran C

shri dharmasthala manjunatheshwara college of ayurveda hospital and research centre kuthpady udupi

kiranasdm@gmail.com9448953038

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026